Key result
Edoxaban will be evaluated for safety and efficacy compared to standard of care in the planned phase 3 ENNOBLE-ATE trial of children with cardiac diseases at risk of thromboembolism, with no clinical results reported yet.
Why the study?
Children with cardiac diseases face significant morbidity and mortality from thromboembolism, but currently used anticoagulants have limitations including subcutaneous administration and frequent monitoring.
Does edoxaban improve safety compared to standard of care in children with cardiac diseases at risk of thromboembolism?
RCT (n=150)
Open-label
2:1
Yes
Does edoxaban improve safety compared to standard of care in children with cardiac diseases at risk of thromboembolism?
This paper describes the rationale and design of the ENNOBLE-ATE trial, which will evaluate the safety and efficacy of edoxaban versus standard of care in children with cardiac diseases.
Answers are grounded in this paper and cite their sources.
Edoxaban provides a convenient oral option for pediatric thromboprophylaxis; extends adult VTE evidence to children with cardiac disease.
Children with cardiac diseases suffer from significant morbidity and mortality secondary to thromboembolic complications. Anticoagulant agents currently used for thromboprophylaxis have many limitations, including subcutaneous administration (low molecular weight heparins) and requirement for frequent monitoring via venipuncture (vitamin K antagonists). Edoxaban is an oral direct factor Xa inhibitor without need of monitoring. In the treatment of venous thromboembolism in adults, edoxaban has shown to be effective and safe.This manuscript summarises the rationale and design of a phase 3, open-label, randomised controlled trial to evaluate and compare the safety and efficacy of edoxaban against standard of care (namely, vitamin K antagonist and low molecular weight heparin) in children with cardiac diseases.A goal of 150 children with cardiac diseases at risk of thromboembolic complications who need primary or secondary anticoagulant prophylaxis will be recruited. Eligible children between 6 months and <18 years of age will be randomised in a ratio of 2 to 1 for edoxaban versus standard of care. Randomisation will be stratified based on underlying cardiac disease and concomitant use of aspirin for patients other than Kawasaki disease. The primary outcome will be safety, comprised of major and clinically relevant non-major bleeding in first 3 months of treatment. Bleeding beyond 3 months, symptomatic and asymptomatic thromboembolic events, and pharmacokinetic and pharmacodynamic parameters will be evaluated as secondary outcomes.Randomised controlled anticoagulation trials are challenging in children. This study will evaluate a potentially valuable alternative of oral anticoagulant prophylactic use in children with cardiac diseases.
No takes yet. Share an insight, caveat, or question.
Bhatt et al. (2021) conducted an RCT in Cardiac diseases at risk of thromboembolism (n=150). Edoxaban vs. Standard of care (vitamin K antagonist or low molecular weight heparin) was evaluated on Composite of major and clinically relevant non-major bleeding in the first 3 months of treatment. Edoxaban will be evaluated for safety and efficacy compared to standard of care in the planned phase 3 ENNOBLE-ATE trial of children with cardiac diseases at risk of thromboembolism, with no clinical results reported yet.
Synapse has enriched 10 related papers. Consider them for comparative context: